scholarly journals The impact of everolimus in reducing cytomegalovirus events in kidney transplant recipients on steroid-avoidance strategy: 3-year follow-up of a randomized clinical trial

2018 ◽  
Vol 31 (12) ◽  
pp. 1345-1356 ◽  
Author(s):  
Tainá Veras de Sandes-Freitas ◽  
Petrucia Maria Antero Pinheiro ◽  
Maria Luíza de Mattos Brito Oliveir Sales ◽  
Celi Melo Girão ◽  
Érika Fernandes Campos ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Avoidance Strategy ◽  
The Impact ◽  
Steroid Avoidance

A randomized clinical trial comparing Nitrofurazone‐coated and uncoated urinary catheters in kidney transplant recipients: Results from a pilot study

2018 ◽  
Vol 21 (2) ◽  
pp. e13031 ◽  
Author(s):  
Fernando Gatti Menezes ◽  
Luci Corrêa ◽  
Jose Osmar Medina‐Pestana ◽  
Wilson Ferreira Aguiar ◽  
Luis Fernando Aranha Camargo
Keyword(s):  
Clinical Trial ◽  
Pilot Study ◽  
Randomized Clinical Trial ◽  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Urinary Catheters

scholarly journals Antibody Responses after a Third Dose of COVID-19 Vaccine in Kidney Transplant Recipients and Patients Treated for Chronic Lymphocytic Leukemia

Vaccines ◽  
2021 ◽  
Vol 9 (10) ◽  
pp. 1055
Author(s):  
Julien Marlet ◽  
Philippe Gatault ◽  
Zoha Maakaroun ◽  
Hélène Longuet ◽  
Karl Stefic ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Kidney Transplant ◽  
Lymphocytic Leukemia ◽  
Antibody Responses ◽  
Moderate Increase ◽  
Immunocompromised Patients ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
The Impact

The impact of a third dose of COVID-19 vaccine on antibody responses is unclear in immunocompromised patients. The objective of this retrospective study was to characterize antibody responses induced by a third dose of mRNA COVID-19 vaccine in 160 kidney transplant recipients and 20 patients treated for chronic lymphocytic leukemia (CLL). Prevalence of anti-spike IgG ≥ 7.1 and ≥ 30 BAU/mL after the third dose were 47% (75/160) and 39% (63/160) in kidney transplant recipients, and 57% (29/51) and 50% (10/20) in patients treated for CLL. Longitudinal follow-up identified a moderate increase in SARS-CoV-2 anti-spike IgG levels after a third dose of vaccine in kidney transplant recipients (0.19 vs. 5.28 BAU/mL, p = 0.03) and in patients treated for CLL (0.63 vs. 10.7 BAU/mL, p = 0.0002). This increase in IgG levels had a limited impact on prevalence of anti-spike IgG ≥ 30 BAU/mL in kidney transplant recipients (17%, 2/12 vs. 33%, 4/12, p = 0.64) and in patients treated for CLL (5%, 1/20 vs. 45%, 9/20, p = 0.008). These results highlight the need for vaccination of the general population and the importance of non-medical preventive measures to protect immunocompromised patients.

scholarly journals The Impact of Self-Care Education with Teach-Back Method on Self-Esteem in Kidney Transplant Recipients: A Clinical Trial

2020 ◽  
Vol 28 (3) ◽  
pp. 154-162
Author(s):  
Masoumeh Hemmati Maslak Pak ◽  
◽  
Farzin Mollazadeh ◽  
Hamidreza Khalkhali ◽  
Saeed Abkhiz ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Kidney Transplant ◽  
Self Care ◽  
Self Esteem ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Care Education ◽  
The Impact

scholarly journals Immunosuppression minimization in kidney transplant recipients hospitalized for COVID-19

2021 ◽  
Author(s):  
Paula Anton Pampols ◽  
Hernando Trujillo ◽  
Edoardo Melilli ◽  
Blanca Urban ◽  
Justo Sandino ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
De Novo ◽  
Graft Function ◽  
Immunosuppressive Agent ◽  
Immunosuppressive Drugs ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Immunosuppressed Patients ◽  
The Impact

Abstract Background Immunosuppressed patients such as kidney transplant recipients (KTs) have increased mortality risk in the setting of coronavirus disease 2019 (COVID-19). The role and management of chronic immunosuppressive therapies during COVID-19 must be characterized. Methods Herein, we report the follow-up of a cohort of 47 KTs admitted at two Spanish Kidney Transplant Units, who survived COVID-19. The impact of the management of immunosuppression during COVID-19 on graft function and immunologic events was evaluated. Results At least one immunosuppressive agent was withdrawn in 83% of patients, with antimetabolites being the most frequent. Steroids were generally not stopped and the dose was even increased in 15% of patients as part of the treatment of COVID-19. Although immunosuppressive drugs were suspended during a median time of 17 days, no rejection episodes or de novo donor-specific antibodies were observed up to 3 months after discharge, and no significant changes occurred in calculated panel reactive antibodies. Acute graft dysfunction was common (55%) and the severity was related to tacrolimus trough levels, which were higher in patients receiving antivirals. At the end of follow-up, all patients recovered baseline kidney function. Conclusions Our observational study suggests that immunosuppression in KTs hospitalized due to COVID-19 could be safely minimized.

scholarly journals MO993IMMUNOSUPPRESSION MINIMIZATION IN KIDNEY TRANSPLANT RECIPIENTS HOSPITALIZED FOR COVID-19

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
Paula Anton Pampols ◽  
Hernando Trujillo ◽  
Edoardo Melilli ◽  
Blanca Urban ◽  
Justo Sandino Pérez ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
De Novo ◽  
Graft Function ◽  
Immunosuppressive Agent ◽  
Immunosuppressive Drugs ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Immunosuppressed Patients ◽  
The Impact

Abstract Background and Aims Immunosuppressed patients such as kidney transplant recipients (KTs) have increased mortality risk in the setting of coronavirus disease 2019 (COVID-19). The role and management of chronic immunosuppressive therapies during COVID-19 must be characterized. Method Herein, we report the follow-up of a cohort of 47 KTs admitted at two Spanish Kidney Transplant Units who survived COVID-19. The impact of the management of immunosuppression during COVID-19 on graft function and immunologic events was evaluated. Results At least one immunosuppressive agent was withdrawn in 83% of patients, with antimetabolites being the most frequent. Steroids were generally not stopped and the dose was even increased in 15% of patients as part of the treatment of COVID-19. Although immunosuppressive drugs were suspended during a median time of 17 days, no rejection episodes neither de novo donor specific antibodies were observed up to 3 months after discharge, and no significant changes occurred in calculated panel reactive antibodies. Acute graft dysfunction was common (55%) and the severity was related to tacrolimus trough levels, which were higher in patients receiving antivirals. At the end of follow-up, all patients recovered baseline kidney function. Conclusion Our observational study suggests that immunosuppression in KTs hospitalized due to COVID-19 could be safely minimized.    

Sign in / Sign up

Export Citation Format

Share Document